Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 31OTHER 24NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 71Head & Neck 38Gynecologic 37Gastrointestinal 34Other solid neoplasm 28CNS 26Genitourinary 21Lymphoid 11Endocrine 7Dermatologic 6Sarcoma 4Other hematologic neoplasm 4Breast 4Tumor-Agnostic 3Plasma cell 1NET 1Classical hematology 1

Conditions

Neoplasms 2Neoplasms, Unknown Primary 1

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Cisplatin × Tumor-Agnostic × Clear all
NCT02723864 2022-02-08

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
53 enrolled 20 charts
Tumor-Agnostic

Neoplasms

NCT00678132 2018-07-05

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
23 enrolled
Tumor-Agnostic

Neoplasms

NCT00022178 2013-09-20

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

National Cancer Institute (NCI)

Phase 3 Unknown
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡